Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) traded up 4.1% during trading on Wednesday . The company traded as high as $8.26 and last traded at $8.19, with a volume of 530,045 shares trading hands. The stock had previously closed at $7.87.

A number of equities analysts recently weighed in on ACHN shares. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a research report on Tuesday, April 26th. Leerink Swann reaffirmed a “market perform” rating and set a $9.00 price objective (up from $7.00) on shares of Achillion Pharmaceuticals in a research report on Wednesday, May 4th. Jefferies Group reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Thursday, May 5th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $10.00 price objective on shares of Achillion Pharmaceuticals in a research report on Monday, June 6th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $10.00.

The company has a 50 day moving average price of $8.76 and a 200-day moving average price of $8.10. The company’s market cap is $1.12 billion.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.01. During the same quarter in the prior year, the business posted ($0.17) earnings per share. On average, analysts forecast that Achillion Pharmaceuticals Inc. will post ($0.65) EPS for the current year.

A number of large investors have bought and sold shares of the company. Morgan Stanley increased its stake in shares of Achillion Pharmaceuticals by 738.4% in the fourth quarter. Morgan Stanley now owns 233,221 shares of the biopharmaceutical company’s stock valued at $2,517,000 after buying an additional 205,405 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Achillion Pharmaceuticals by 10.1% in the fourth quarter. ProShare Advisors LLC now owns 126,923 shares of the biopharmaceutical company’s stock valued at $1,370,000 after buying an additional 11,681 shares in the last quarter. Swiss National Bank increased its stake in shares of Achillion Pharmaceuticals by 6.8% in the fourth quarter. Swiss National Bank now owns 152,400 shares of the biopharmaceutical company’s stock valued at $1,644,000 after buying an additional 9,700 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Achillion Pharmaceuticals by 36.8% in the fourth quarter. Marshall Wace LLP now owns 970,862 shares of the biopharmaceutical company’s stock valued at $10,476,000 after buying an additional 261,007 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Achillion Pharmaceuticals by 14.0% in the fourth quarter. Rhumbline Advisers now owns 117,525 shares of the biopharmaceutical company’s stock valued at $1,268,000 after buying an additional 14,425 shares in the last quarter.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.